Home » Stocks » TBIO

Translate Bio, Inc. (TBIO)

Stock Price: $34.42 USD 4.42 (14.73%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
After-hours: $34.40 -0.02 (-0.06%) Jul 26, 7:11 PM
Market Cap 2.26B
Revenue (ttm) 168.76M
Net Income (ttm) -12.98M
Shares Out 75.23M
EPS (ttm) -0.18
PE Ratio n/a
Forward PE 29.67
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $34.42
Previous Close $30.00
Change ($) 4.42
Change (%) 14.73%
Day's Open 30.49
Day's Range 30.27 - 34.80
Day's Volume 1,623,943
52-Week Range 11.91 - 34.80

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

LEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicine...

2 weeks ago - GlobeNewsWire

Sanofi (SNY) and Translate Bio begin a phase I study on an mRNA-based vaccine candidate against seasonal influenza.

Other stocks mentioned: SNY
1 month ago - Zacks Investment Research

Sanofi Pasteur, vaccine unit of Sanofi SA (NASDAQ: SNY) and Translate Bio Inc (NASDAQ: TBIO) have initiated a Phase 1 trial evaluating an mRNA-based investigational vaccine against seasonal influenza. T...

Other stocks mentioned: SNY
1 month ago - Benzinga

-- Trial will evaluate potential of next generation of influenza vaccines with combined mRNA technology and flu vaccine development expertise -- -- Positive preclinical safety and immunogenicity data fo...

1 month ago - GlobeNewsWire

LEXINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicine...

1 month ago - GlobeNewsWire

-- $50 million milestone payment to be received this month for successful manufacturing, release, and delivery of clinical drug product to support influenza mRNA vaccine clinical trial anticipated to be...

1 month ago - GlobeNewsWire

LEXINGTON, Mass., May 24, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines...

2 months ago - GlobeNewsWire

Translate Bio Inc (NASDAQ: TBIO) has presented positive results from a preclinical study of its mRNA-based therapeutic designed to treat the pulmonary component of primary ciliary dyskinesia (PCD). Muta...

2 months ago - Benzinga

– Positive results suggest potential for an mRNA-based therapeutic to correct ciliary function in patients with PCD due to DNAI1 mutations –

2 months ago - GlobeNewsWire

Translate Bio, Inc. (TBIO) delivered earnings and revenue surprises of -11.11% and -12.40%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

-- Advanced infectious disease vaccine programs with Sanofi Pasteur through initiation of COVID-19 clinical trial and publication of preclinical results; Influenza trial anticipated to begin mid-year --...

2 months ago - GlobeNewsWire

LEXINGTON, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines...

2 months ago - GlobeNewsWire

Translate Bio, Inc. (TBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Here is what you should know about investing in these life changing technologies.

Other stocks mentioned: BNTX, CHNA, CNCR, CRSP, CVAC, EDIT, IBB ...
2 months ago - Zacks Investment Research

LEXINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicin...

2 months ago - GlobeNewsWire

-- Multiple antigen constructs, including the construct used in MRT5500, induced potent neutralizing antibodies against SARS-CoV-2 in preclinical studies in multiple species -- -- Efficacy demonstrated ...

3 months ago - GlobeNewsWire

- - Seasoned healthcare executive, Brendan Smith, appointed as Chief Financial Officer, bringing strategic operations and financial leadership -- -- Appointments enhance capabilities across pulmonary pr...

3 months ago - GlobeNewsWire

-- 20 years of combined industry, medical and academic expertise in pulmonary and rare disease to support continued advancement of mRNA therapeutic pipeline -- LEXINGTON, Mass., March 22, 2021 (GLOBE NE...

4 months ago - GlobeNewsWire

Investors are disappointed with the company's latest clinical update.

4 months ago - The Motley Fool

Translate Bio could be facing a two-year delay for its cystic fibrosis drug, an analyst said Thursday as TBIO stock crashed on a testing flop. The drug didn't improve lung function.

4 months ago - Investors Business Daily

Translate Bio (TBIO) announces data from second interim analysis of phase I/II study evaluating MRT5005 in patients with cystic fibrosis. The candidate fails to improve lung function in patients.

4 months ago - Zacks Investment Research

Translate Bio Inc (NASDAQ: TBIO) revealed its second interim analysis from Phase 1/2 clinical trial evaluating MRT5005 in patients with cystic fibrosis (CF). MRT5005 is an mRNA product candidate designe...

4 months ago - Benzinga

-- First inhaled mRNA therapeutic delivered in multiple doses to the lungs of CF patients is generally safe and well tolerated; no observed pattern of increases in ppFEV1 -- -- Data supports advancing m...

4 months ago - GlobeNewsWire

The phase I/II clinical study on Sanofi (SNY)/Translate Bio's (TBIO) COVID-19 vaccine candidate will assess its safety, immune response and reactogenicity.

Other stocks mentioned: SNY, GSK, MRNA
4 months ago - Zacks Investment Research

The two mRNA vaccines licensed for Covid-19 have proven highly effective, according to clinical and real-world studies.

Other stocks mentioned: SNY
4 months ago - Forbes

Sanofi SA (NASDAQ: SNY) and Translate Bio Inc (NASDAQ: TBIO) have started a human trial of their mRNA COVID-19 vaccine candidate, dubbed MRT5500. The event has triggered a milestone payment of $25 milli...

Other stocks mentioned: SNY
4 months ago - Benzinga

Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate

4 months ago - GlobeNewsWire

-- Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels -- -- Expected to enroll 415 participants; interim results expecte...

4 months ago - GlobeNewsWire

Translate Bio, Inc. (TBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

LEXINGTON, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicin...

4 months ago - GlobeNewsWire

LEXINGTON, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicine...

5 months ago - GlobeNewsWire

LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicine...

5 months ago - GlobeNewsWire

-- MRT5005 is the first clinical-stage mRNA therapeutic with nebulized delivery to the lung and first to be administered in multiple doses for the treatment of a chronic genetic disease -- -- Completed ...

6 months ago - GlobeNewsWire

Big drugmakers could be attracted to these smaller players with promising pipelines.

Other stocks mentioned: BLUE, EDIT
6 months ago - The Motley Fool

TBIO is a leader in mRNA therapeutics. Its cystic fibrosis program has interim data from a phase 1 study.

6 months ago - Seeking Alpha

We discuss six biotech/drug stocks, NVAX, VXRT, MRNA, TBIO, INO and BNTX that have more than doubled in 2020 on the back of their progress in coronavirus vaccine development.

Other stocks mentioned: BNTX, INO, MRNA, NVAX, VXRT
7 months ago - Zacks Investment Research

LEXINGTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicine...

7 months ago - GlobeNewsWire

In the race to develop a coronavirus vaccine, Pfizer and its partner BioNTech have a lead, closely followed by Moderna. However, four other biotechs, NVAX, TBIO, INO and VXRT, still hold potential to ga...

Other stocks mentioned: INO, NVAX, VXRT
7 months ago - Zacks Investment Research

Great efficacy results for mRNA COVID-19 vaccines so far could bode well for these three stocks.

Other stocks mentioned: ARCT, CVAC
8 months ago - The Motley Fool

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicine...

8 months ago - GlobeNewsWire

-- Advances Phase 1/2 clinical trial of MRT5005 for the treatment of cystic fibrosis ( CF ) with resumption of COVID-impacted enrollment and dosing -- -- Presented promising preclinical data at NACFC fr...

8 months ago - GlobeNewsWire

Translate's Covid-Vaccine, And Other News: The Good, Bad And Ugly Of Biopharma

9 months ago - Seeking Alpha

The market leader in flu vaccines is trailing in the race to find an effective coronavirus vaccine.

Other stocks mentioned: SNY
9 months ago - The Motley Fool

Translate Bio and Sanofi announced positive preclinical results for their Covid-19 vaccine candidate in mice and non-human primates, and said human testing will start this quarter; TBIO rose. The post S...

Other stocks mentioned: SNY
9 months ago - Investors Business Daily

Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies

Other stocks mentioned: SNY
9 months ago - GlobeNewsWire

- - Lead candidate MRT5005 leverages Translate Bio’s proprietary LNP and mRNA platform and is the o nly clinical - stage mRNA therapeutic in development for the treatment of CF -- - - Second CF program,...

9 months ago - GlobeNewsWire

LEXINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medic...

10 months ago - GlobeNewsWire

-- Expanded collaboration with partner Sanofi Pasteur for all infectious diseases further unites Translate Bio’s leading mRNA technology and large-scale manufacturing with Sanofi’s world class vaccine d...

11 months ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $TBIO #TBIO--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Translate Bio, Inc.

11 months ago - Business Wire

Is (TBIO) Outperforming Other Medical Stocks This Year?

11 months ago - Zacks Investment Research

About TBIO

Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was ... [Read more...]

Industry
Biotechnology
IPO Date
Jun 28, 2018
Stock Exchange
NASDAQ
Ticker Symbol
TBIO
Full Company Profile

Financial Performance

In 2020, Translate Bio's revenue was $138.81 million, an increase of 1,678.72% compared to the previous year's $7.80 million. Losses were -$53.79 million, -52.52% less than in 2019.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Translate Bio stock is "Strong Buy." The 12-month stock price forecast is 25.38, which is a decrease of -26.26% from the latest price.

Price Target
$25.38
(-26.26% downside)
Analyst Consensus: Strong Buy